Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Investment Management Corp of Ontario

Investment Management Corp of Ontario raised its holdings in Moderna, Inc. (NASDAQ:MRNA) by 49.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 10,868 shares of the company’s stock after acquiring an additional 3,600 shares during the period. Investment Management Corp of Ontario’s holdings in Moderna were worth $726,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in MRNA. Simplicity Wealth LLC increased its stake in Moderna by 31.6% in the second quarter. Simplicity Wealth LLC now owns 4,838 shares of the company’s stock valued at $575,000 after purchasing an additional 1,161 shares during the last quarter. LPF Advisors LLC acquired a new position in shares of Moderna during the 2nd quarter valued at about $461,000. Czech National Bank lifted its holdings in shares of Moderna by 8.9% during the 2nd quarter. Czech National Bank now owns 63,536 shares of the company’s stock worth $7,545,000 after acquiring an additional 5,170 shares during the period. Granite Bay Wealth Management LLC acquired a new stake in shares of Moderna in the second quarter worth approximately $524,000. Finally, Sequoia Financial Advisors LLC grew its holdings in Moderna by 7.1% in the second quarter. Sequoia Financial Advisors LLC now owns 8,722 shares of the company’s stock valued at $1,036,000 after purchasing an additional 575 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In other news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,850 shares of company stock worth $134,560. Insiders own 15.70% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $44.44 on Friday. Moderna, Inc. has a 1-year low of $35.80 and a 1-year high of $170.47. The stock has a market cap of $17.10 billion, a P/E ratio of -7.64 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a 50-day moving average of $50.27 and a two-hundred day moving average of $88.25.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter last year, the firm earned ($1.39) EPS. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. On average, research analysts expect that Moderna, Inc. will post -9.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MRNA. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. The Goldman Sachs Group reduced their target price on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Leerink Partners dropped their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research note on Tuesday, September 17th. TD Cowen reduced their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Finally, Wolfe Research assumed coverage on shares of Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price for the company. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $83.33.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.